PCSK1 and Prader-Willi syndrome: Although diverse anti-obesity drugs are currently approved for the treatment of obesity (orlistat, naltrexone/bupropion, and liraglutide 3.0 mg), none has been specifically studied in patients with PWS or PCSK1 deficiency.